Are DNA methylation markers ready for colorectal cancer detection?

Cancer Biology and Therapy

Volumn 9, Issue 11, 2010, Pages 872-874

  De Paoli, Vania M ^a,c   Chen, Chun Hao ^b   Cheng, Yu Wei ^c  

^a HOSTOS COMMUNITY COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AKAP12; Cancer detection; Colorectal cancer; DNA methylation; Melting curve assay; Sensitivity; Specificity

Indexed keywords

A KINASE ANCHOR PROTEIN 12; CARRIER PROTEINS AND BINDING PROTEINS; DNA; UNCLASSIFIED DRUG;

CANCER GROWTH; COLORECTAL ADENOCARCINOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; DNA METHYLATION; HUMAN; NOTE;

A KINASE ANCHOR PROTEINS; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; DNA METHYLATION; HUMANS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954420635     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.11.12263     Document Type: Note

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
3. Sawyers CL. The cancer biomarker problem. Nature 2008; 452:548-52.
4. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21:5427-40. (Pubitemid 34983479)
5. Zitt M, Zitt M, Muller HM. DNA methylation in colorectal cancer - impact on screening and therapy monitoring modalities? Dis Markers 2007; 23:51-71.
6. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130-60.
7. Liu W, Guan M, Su B, Ye C, Li J, Zhang X, et al. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with dukes' stage. Cancer Biol Ther 2010; 9.
8. Xia W, Gelman IH. Mitogen-induced, FAKdependent tyrosine phosphorylation of the SSeCKS scaffolding protein. Exp Cell Res 2002; 277:139-51.
9. Gelman IH. The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002; 7:1782-97.
10. Lin X, Gelman IH. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res 1997; 57:2304-12. (Pubitemid 27247053)
11. Lin X, Nelson P, Gelman IH. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)→S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 2000; 20:7259-72.
12. Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 2004; 23:7095-103.
13. Jo U, Whang YM, Kim HK, Kim YH. AKAP12alpha is Associated with Promoter Methylation in Lung Cancer. Cancer Res Treat 2006; 38:144-51.
14. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 2006; 131:797-808.
15. Flotho C, Paulun A, Batz C, Niemeyer CM. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. Br J Haematol 2007; 138:644-50.
16. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 2008; 17:111-7.
17. Liu W, Guan M, Su B, Li J, Ma W, Liu C, et al. Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: Application in colorectal cancer. Clin Chim Acta 2010; 411:940-6.
18. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005; 102:16368-73.
19. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97:1124-32.
20. Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, Campbell ME, et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 2007; 16:2686-96.
21. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54:414-23.
22. Grutzmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008; 3:3759.
23. deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009; 55:1337-46.
24. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009; 136:459-70.
25. Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res 2008; 14:6005-13.
26. Cheng YW, Idrees K, Shattock R, Khan SA, Zeng Z, Brennan CW, et al. Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer 2009.